Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis

Dialysis patients are at increased risk of severe coronavirus disease 2019 (COVID-19) infections.1 Therefore, they are considered as being a priority population for COVID-19 vaccination. Because immune responses against vaccines are considerably reduced in this population,2 a vaccination strategy including 3 doses of vaccine has been recommended for dialysis patients. However, few data exist concerning humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with 3 doses of BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis (HD).
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research